

**ASSESSMENT OF HER2 EXPRESSION STATUS,
TUMOUR BUDDING AND POORLY DIFFERENTIATED
CLUSTERS IN COLORECTAL CANCER**

BY

HAROON FIROOZ

A thesis submitted in fulfilment of the requirement for the
degree of Master of Medical Sciences

Kulliyyah of Medicine

International Islamic University Malaysia

JULY 2021

ABSTRACT

In Malaysia, colorectal cancer (CRC) is the second most common tumour. Tumour budding (TB) and poorly differentiated clusters (PDC) have been shown to be independent prognostic factors in CRC, that may allow for stratification of patients into more meaningful risk categories than those defined by TNM staging. However, these parameters are not routinely incorporated as part of the histopathological assessment. The role of Human Epidermal Growth Factor Receptor 2 (HER2) as a prognostic biomarker in CRC remains uncertain. Negative prognostic impact of HER2 expression has been proposed with a trend towards worse overall survival. Therefore, we aimed to evaluate the TB, PDC and HER2 expression status in our CRC cases and assess their associations with the established prognostic clinicopathological parameters including lymphovascular invasion, lymph node metastasis, tumour grade and tumour stage (pTNM). For evaluation of TB and PDC, hematoxylin and eosin-stained slides prepared from tissue blocks of 129 CRC cases diagnosed from 1st January 2017 to 31st December 2018, in Hospital Tengku Ampuan Afzan (HTAA) and Sultan Ahmad Shah Medical Centre @ IIUM, Kuantan Pahang. PDC, and TB according to the International Tumour Budding Consensus Conference (ITBCC) criteria were scored. For HER2 expression, IHC and FISH analysis were utilized, following HERACLES diagnostic criteria. Results: For TB, of the 129 cases studied, 63 (48.8%), 35 (27.2%) and 31 (24%) cases were classified as budding 1, budding 2, and budding 3, respectively. As for PDC, 73 (56.6%), 33 (25.6%) and 23 (17.8%) cases were classified as grade 1, grade 2 and grade 3, respectively. High TB and PDC grades were significantly associated with lymphovascular invasion ($p < 0.05$), nodal metastasis ($p < 0.05$) and high pTNM stage ($p < 0.05$). For HER2, 5 (3.9%) cases were positive for HER2 expression by IHC (scores 3+), equivocal 9 (7.0%) and negative 115 (89.1%). All HER2 2+ and 3+ (total 14 cases) was further evaluated by FISH analysis and *HER2* gene amplification was seen in 4 cases. There is an association between HER2 protein expression status and pTNM stage ($p < 0.005$). Otherwise, there is no correlation between HER2 protein expression with lymphovascular invasion, nodal metastasis, tumour grade, tumour budding or poorly differentiated clusters. Conclusion: There is strong evidence to suggest that tumour budding, and poorly differentiated clusters are an adverse prognostic factor. Our findings indicate that HER2 overexpression occurs in a small population of CRC cases and may benefit with HER2 targeted therapy.

خلاصة البحث

زيامتلا (TB) عويش مارولاً عاوناً رثكاً يثب دقل. ايزيلام يف ا مرولا ومن نأ) CRC) طرس ربتعي كلت نم قيمها رثكاً رطاحم تائف بلا بضرملل يقبطلا، CRC يف ؤلقتسم ؤيؤبنت لماوع يه) PDC) ؤفيعضلا لتكلاو يضرملا يحيرشتلا ميقتلا نم عزجك. جيردتلا . رود لازى TNM ميسقتلاب حمست دق يتلاو ؤددحملا ؤطساوب رشؤمك دكؤم ريغ لفظلا قوقح ؤيافتا يف صيخشنتل يويح. ريبعتل ييلسلا ريذنلا ريثأتلا حارتقا مت HER2 لا لذكو PDC و) TB) مرولا ومن ميقت بلا فدهن انك ، كذل. ماع لكشب أوسأ ؤاقب وحن هجوت عم HER2 رييعملاب مهتاطابترا ميقتو ثيبخ مرو ، ؤيومدلا ؤيعولأاو يوافملا CRC تلااح يف HER2 نع ريبعتلا ؤلااح ك يناعولا وزغلا كذ يف امب ؤخسارلا ريذنلا ؤيكنيلكلا مرولا ومن ميقتل. مرولا ؤلحرمو ؤيوافميلا ؤدقلا يف نم CRC نم 129 ؤلااح) E&H) هيجيسن حئارش ترضح و نيليسكوتاميهايب تغبصو نيزويلااب PDC و TB يف نفشتسم 2018 ريمسيد 31 بلا 2017 ، Tengku Ampuan Afzan (HTAA) اهصيخشنت مت 1 ريانى قفو ا. مارولاً ومن TB و PDC ، ليچست مت. جناهاب ناتناوك IIUM بيطلا هاش دمحاً ناطلس زكرمو HERACLES. قفو ، رييعمل ا FISH و IHC عامجلا يلودلا رمتؤملا رييعمل ليلحت مادختسا مت نيب نم ، 129 تمت ؤلااح فينصت مت ، اهتسارد 63 و 35 و 31) TB) ؤيصيخشنتلا ؤجيتن: ضرمل ؤبسنلاب فينصت مت دقف ، 73 PDC ؤنشان اهنأ بلع ؤلااح 1 ؤنشان ؤلاحو 2 ؤنشان ؤلاحو 3 ل ؤبسنلاب امأ. يلاوتلا بلع وزغ عم ريبك PDC و ؤعقرملا) TB) و 33 و 23 تاجرد اهنأ بلع ؤلااح 1 و 2 و 3 تاجرد تطبترا. يلاوتلا بلع HER2 (. ينيئوربلا ريبعتلا نيب ؤقلاع دجوت لا ، كذ فلاح P 005.0) ؤلحرمو pTNM ؤيلاع p). لكشب وزغلاو لكشب ؤنيابتم ناعومجم وأ مرولا معرفتو ، يدقع ثيبخ مرو ، يوافملا يناعولا جاتنتسا. ئيس : لماع يه ئيس لكشب ؤزيامتلا ديفانعلو مرولا ومن نأ بلا ريشت قيوق ؤلدأ كانه ريشت. راض يؤبنت نيئورب نع ريبعتلا يف عم تاساردلا نم ديزم CRC تلااح نم ؤريغص ؤبسن يف ئدحي HER2 طارفلا نأ بلا اهيل انلصوت يتلا جئاتنلا بلا ؤجاح كانه نوكتسو ربكاً تانيع ماجحاً

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Medical Sciences

.....
Azliana Abd Fuaat
Supervisor

.....
Naznin Muhammad
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Medical Sciences

.....
Khairunisa Ahmad Affandi
Internal Examiner

This thesis was submitted to the Department of Pathology and Laboratory Medicine and is accepted as a fulfilment of the requirement for the degree of Master of Medical Sciences

.....
Norlelawati A. Talib
Head, Department of Pathology
and Laboratory Medicine

This thesis was submitted to the Kulliyah of Medicine and is accepted as a fulfilment of the requirement for the degree of Master of Medical Sciences.

.....
Azmi Md Nor
Dean, Kulliyah of Medicine


DECLARATION

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Haroon Firooz

Signature.....

Date



INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**ASSESEMENT OF HER2 EXPRESSION STATUS, TUMOUR
BUDDING AND POORLY DIFFERENTIATED CLUSTERS IN
COLORECTAL CANCER**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 by Haroon Firooz and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledge that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Haroon Firooz

.....

Signature

.....


Date

DEDICATION

TO MY PARENTS

TO MY TEACHERS AND

TO MY BELOVED WIFE AND DAUGHTER



ACKNOWLEDGEMENTS

All praises belong to Allah the most merciful, whose guidance and help provided me the strength to accomplish this thesis.

I would like to express my sincere gratitude to my supervisor Asst. Prof. Dr. Azliana Abd Fuaat, who has facilitated every aspect of this hard work and supervised my study whole period by remarkable assistance, continuous persuasion, strong patience, and valuable suggestions.

It is an honour to state that my co-supervisors Prof. Dr. Naznin Muhammad, Assoc. Prof. Dr. Norlelawati A. Talib and Prof. Dr. Azmi Md Nor with their exceptional capabilities, kindness, and motivation made easy accomplishing the tasks throughout my study.

I would like to thank the Dean of Kulliyah of Medicine, IIUM Prof. Dr. Azmi Bin Md Nor, and the Deputy Dean of Research & Postgraduate Affairs, Prof. Dr. Jamalludin Ab Rahman, for providing and managing the opportunity to fulfill my master's degree in the prestigious International Islamic University Malaysia.

I also express my gratitude to Muhammad Hanif, for his advice and technical assistance in immunohistochemistry, Sr. Nur Amalina Amirah, for her help and collaboration with the FISH test and Sr. Nur Farhana Zulkefli for her administrative tasks.

Finally, I would like to express my gratitude to the Higher Education Development Project (HEDP), to Ministry of Higher Education, Afghanistan (MOHE), and to Herat University for granting me the scholarship for my master's degree.

TABLE OF CONTENTS

Abstract.....	ii
Abstract in Arabic.....	iii
Approval page	iv
Declaration.....	v
Copyright Page.....	vi
Acknowledgements	vii
Tables of Contents	viii
List of Tables	ix
List of Figures.....	xiv
List of Abbreviations	xvi
CHAPTER ONE: INTRODUCTION	1
1.1 Background.....	1
1.2 Justification of the study.....	3
1.3 Research questions.....	5
1.4 Hypothesis	6
1.5 Objectives	7
1.5.1 General Objective.....	7
1.5.2 Specific Objectives.....	7
CHAPTER TWO: LITERATURE REVIEW	8
2.1 Epidemiology of colorectal cancer	8
2.2 Risk factor of colorectal cancer	11
2.3 Pathogenesis of colorectal cancer.....	12
2.3.1. Chromosomal Instability	12
2.3.1.1. APC/B-Catenin	13
2.3.1.2. TP53.....	14
2.3.1.3 KRAS.....	15
2.3.2. Microsatellite Instability Pathway.....	16
2.3.3 CpG Island Methylator Phenotype (CIMP)	18
2.4 Clinical manifestation of colorectal cancer	19
2.4.1 Constipation	20
2.4.2 Fatigue.....	20
2.4.3 Occult Blood and Rectal Bleeding.....	20
2.4.4 Bowel Obstruction.....	20
2.4.5 Change in Bowel Habit	20
2.4.6 Weight Loss.....	21
2.4.7 Abdominal Pain.....	21

2.4.8 Iron Deficiency Anemia.....	21
2.4.9 Signs of Colorectal Cancer.....	21
2.5. Diagnosis of colorectal cancer	22
2.5.1 Blood Test	22
2.5.2 Fecal Occult Blood Test (FOBT).....	22
2.5.3 Colonoscopy.....	23
2.5.4 Biopsy.....	23
2.5.5 Molecular testing of tumor.....	23
2.5.6 Computed Tomography (CT scan).....	24
2.5.7 Magnetic Imaging Resonance (MRI).....	24
2.5.8 Positron Emission Tomography (PET-Scan)	24
2.6 Macroscopic appearance of colorectal cancer	24
2.7 Microscopic types and grading of crc.....	25
2.8 Staging of colorectal cancer.....	26
2.8.1 Dukes' staging for colorectal cancer	26
2.8.2 Pathologic stage classification (ptnm, ajcc 8th edition).....	27
2.8.3 TNM clinical classification	29
2.9 Pathology reporting of corectal cancer	31
2.10 Screening of colorectal cancer.....	31
2.11 Prevention of colorectal cancer	33
2.12 Colorectal cancer treatment	33
2.13 Prognosis of colorectal cancer	34
2.14 Prognostic and predictive molecular biomarkers	34
2.15 HER2 in colorectal cancer	35
2.15.1 Assessment of HER2 status	37
2.15.1.1 Immunohistochemistry (IHC).....	37
2.15.1.2 Fluorescent in situ hybridization (FISH)	40
2.16 Prognostic histomorphological factors of colorectal cancer.....	41
2.16.1 Tumour Budding	42
2.16.2 Poorly Differentiated Cluster:	47
CHAPTER THREE: METHODOLOGY.....	49
3.1 Ethical approval and consideration of the study.....	49
3.2 Study design and specimen collection.....	50
3.3 Sample size calculation.....	51
3.4 Inclusion criteria:	52
3.5 Exclusion criteria	52
3.6 Flow chart	53
3.7 Haematoxylin and eosin staining.....	54
3.7.1 Equipment and material used for h&e staining.....	54
3.7.2 Slide preparation	55
3.7.2.1 Procedure	55

3.8 Tumour budding assesment	61
3.9 Poorly differentiated clusters assesement	63
3.10 Immunohistochemistry	64
3.10.1 Principle	64
3.10.2 Equipment And Material	65
3.10.3 Procedure.....	65
3.10.3.1 Reagent preparation	65
3.10.3.2 Deparaffinization and Rehydration	66
3.10.3.3 Heat Induced Antigen Retrieval (HIER).....	67
3.10.3.4 Immunohistochemistry Staining	67
3.10.3.5 Counter Staining	67
3.10.3.6 Mounting.....	68
3.10.4 HER2 Interpretation and scoring.....	68
3. 11 Fluorescents in situ hybridization (FISH)	70
3.11.1 Procedure.....	70
3.11.1.1 Tissue sectioning and slide preparation	71
3.11.1.2 Reagent Preparation	72
3.11.1.3 Deparaffinization of slides	72
3.11.1.4 Paraffin Pretreatment	74
3.11.1.5 Protease Treatment.....	74
3.11.1.6 Dehydration.....	74
3.11.1.7 Codenaturation and Hybridization	74
3.11.1.8 Post Hybridization Wash	75
3.11.1.9 DAPI Counterstaining.....	75
3.12 Fluorescents in situ hybridization (FISH) interpretation and scoring	76
3.13 Statistical analysis.....	78
CHAPTER FOUR: RESULTS AND FINDINGS.....	79
4.1 Samples.....	79
4.2 Demographic data	79
4.3 Histomorphological characteristic	79
4.4. Tumour budding (TB).....	82
4.5 Poorly differentiated clusters (PDC)	85
4.6 Correlation between tumour budding and poorly differentiated clusters	89
4.7 HER2 protien expression by immunohistochemistry	90
4.8 HER2 amplifications by fluorescent in situ hybridization (FISH)	94
4.9 Concordance between HER2 expression and HER2 gene amplification	95
CHAPTER FIVE: DISCUSSION.....	96
5.1 Discussion.....	96
5.1.1 Demographic characteristics of CRC Subjects	96
5.1.2 Colorectal cancer and tumour budding	97

5.1.3 Colorectal cancer and poorly differentiated clusters.....	99
5.1.4 Tumour budding and PDC in colorectal cancer.	101
5.1.5 Colorectal cancer and HER2 expression.....	101
5.2 Limitation of study	104
5.3 Conclusion.....	105
5.4 Recommendations.....	105
REFERENCES.....	106
APPENDICES.....	122




LIST OF TABLES

Table 3.1	Hematoxylin & Eosin Staining Protocol	58
Table 3.2	Conversion table to adjust and standardize tumor bud count for different microscope types.	62
Table 3.3	Deparaffinization and rehydration of tissue slides	66
Table 3.4	Counterstaining of Immunohistochemistry slides	68
Table 4.1	Clinicopathologic features of study samples (n=129)	81
Table 4.2	Association of tumor budding grades and clinicopathological characteristics	83
Table 4.3	Correlation between tumor budding grades and characteristics	84
Table 4.4	Association of PDC grades and clinicopathological	86
Table 4.5	Correlation between PDC grades and histopathological characteristics	88
Table 4.6	Correlation between poorly differentiated cluster and tumor budding	90
Table 4.7	Association of HER2 protein expression with clinicopathological characteristics	92
Table 4.8	Correlation between HER2 protein expression and tumor TB grades	93
Table 4.9	Correlation between HER2 protein expression and poorly differentiated cluster grades	94
Table 4.10	Concordance between HER2 expression by immunohistochemical staining and <i>HER2</i> gene amplification by fluorescence in situ hybridization	95

LIST OF FIGURES

Figure 2.1	Incidence of CRC in Malaysia in 2020 (The Global Cancer Observatory –March 2020)	10
Figure 2.2	The model of stepwise progression of colorectal cancer as originally proposed by Vogelstein	16
Figure 2.3	An overview of the genetic and epigenetic instability pathways that cause and evolve colorectal cancer	19
Figure 2.4	The four common macroscopic varieties of carcinoma.	25
Figure 2.5	Evaluation of HER2 by immunohistochemistry in colorectal cancer	39
Figure 2.6	Morphology of tumour budding	43
Figure 2.7	Procedure proposed by ITBCC 2016 to record tumour budding in colorectal cancer in day to day diagnosis	46
Figure 2.8	Examples of poorly differentiated clusters (PDC)	48
Figure 3.1	Formalin-fixed paraffin-embedded (FFPE) blocks of colorectal cancer	51
Figure 3.2	Flow chart of laboratory procedure	53
Figure 3.3	Embedding Machine (Leica, Model EG1160, Germany)	55
Figure 3.4	Rotatory Microtome Machine (Leica, Model RM 2255 Germany)	56
Figure 3.5	Water Bath (Leica, Model H1 1210 Germany)	57
Figure 3.6	Leica Autostainer XL ST5010 model (Leica, Germany)	58
Figure 3.7	Light Microscope (Olympus BX51TF, Japan)	60
Figure 3.8	Examples of different tumour budding grades	62
Figure 3.9	Poorly differentiated cluster grades	63
Figure 3.10	Dako Autostainer universal staining system	64
Figure 3.11	IHC staining of HER2	69

Figure 3.12	PathVysion HER2 DNA Kit	71
Figure 3.13	Benchmark digital water bath	72
Figure 3.14	Diamond tipped scribe used for marking slides	73
Figure 3.15	Vysis Hybrite Slide Stainer Model 30102720	73
Figure 3.16	Applying nail polish to prevent coverslip from moving	76
Figure 3.17	Leica VERSA Bright field, Fluorescence & FISH Digital Pathology Scanner	77
Figure 3.18	HER2 amplification in colorectal cancer.	77
Figure 4.1	Tumour budding frequency in colorectal cancer cases (n=129)	82
Figure 4.2	Poorly differentiated cluster (PDC) frequency in CRC cases (n=129)	86
Figure 4.3	Expression of HER 2 staining in CRC cases (n=129)	91



LIST OF ABBREVIATION

%	Percent
≥	Greater or equal to
≤	Lesser of equal to
μg	Microgram
μl	Microliter
5 FU	5 Fluorouracil
ACS	American cancer society
AJCC	American Joint Cancer Committee
APC	Adenomatous polyposis coli
Bd	Budding
BRAF	v-raf murine sarcoma viral oncogene homolog B1
BWL	Body weight loss
CAP	College of American pathologist
CEA	Carcinoembryonic antigen
CEP	Centromeric region of chromosome
CIBH	Change in bowel habit
CIMP	CpG island methylator phenotype
CIN	Chromosomal instability
CT	Computerized tomography
CTG	Computed tomographic colonography
DMMR	Deficient Mismatch Repair
DNA	Deoxyribonucleic
DPX	Dibutylphthalate polystyrene xylene
DRE	Direct rectal exam
EGFR	Epidermal growth factor receptor
FAP	Familial adenomatous polyp

FDA	Food drug administration
FFPE	Formalin-fixed paraffin-embedded
FISH	Fluorescent in situ hybridization
FIT	Fecal immunochemical test
FOBT	Fecal occult blood test
G1	Growth phase I
G2	Growth phase II
GDP	Guanosine diphosphate
GLOBOCAN	Global cancer incidence
GTP	Guanosine-5'-triphosphate
H&E	Haematoxylin and Eosin.
HERACLES	HER2 Amplification for Colorectal Cancer Enhanced Stratification
HIER	Heat induced epitope retrieval
HNPCC	Hereditary nonpolyposis colorectal cancer
HTAA	Hospital Tengku Ampuan Afzan
IDA	Iron deficiency anemia
IHC	Immunohistochemistry
IREC	IIUM Research Ethics Committee
IRL	Integrated Research Lab
ITBCC	International tumour budding consensus conference
KRAS	Kirsten rat sarcoma
KRC	Kulliyyah of Medicine Research Committee
LEF	Lymphoid Enhancer Factor
LVI	Lymphovascular invasion
MLH1	MutL homolog 1
MMR	Mismatch repair gene
MREC	Medical Research and Ethical Committee
MRI	Magnetic resonance imaging
MSI	Microsatellite instability

NMRR	National Medical Research Registry
NRAS	Neuroblastoma RAS viral oncogene homolog
OS	Overall survival
PALM	Pathology and Laboratory Medicine
PCR	Polymerized chain reaction
PDC	Poorly differentiated cluster
PET scan	Positron emission tomography
PIK3CA	phosphatidylinositol 3-kinase catalytic alpha polypeptide
pN	Pathological lymph node stage
PNI	Perineural invasion
RCT	Randomized control trial
SASMEC	Sultan Ahmad Shah Medical Centre
RFS	Relapse free survival
SISH	Silver in situ hybridization
SPSS	Statistical Package for the Social Sciences
TB	Tumour budding
TCF	T cell Factor
TP 53	Tumour protein
UICC	Union for International Cancer Control
UV	Ultra violet
DAPI	4',6-Diamidino-2-Phenylindole
WHO	World health organization
Wnt	'Wingless/Integrated'

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND

Despite expanded access to appropriate healthcare, which has greatly improved cancer detection and treatment, death rates from cancer-related deaths have increased by nearly 40% over the last 40 years (Kuipers et al., 2015). An additional 60% increase is expected in the next 15 years, with 13 million people are estimated to die from cancers in 2030 (Kuipers et al., 2013).

Colorectal cancer (CRC) is one of the most common cancers worldwide (Stewart et al., 2014; Gupta et al., 2018; Siegel et al., 2020). Of the various histologic types and variants of CRC, adenocarcinoma makes up the most CRC cases about 95 % (Rasool et al., 2013; Li et al., 2019). The incidence of CRC across the world showed a wide geographical variation in (Tung et al., 2018). In the United States, CRC is the third most commonly occurring cancer in both men and women and similarly accounts for the second commonest cause of cancer death (Siegel et al., 2020). Approximately 25% of patients have metastatic disease at the time of diagnosis with a 5-year survival rate (Stewart & Wild, 2014; Greally et al., 2018a; Gupta et al., 2018;).

In Malaysia, CRC is the second most common cancer in overall population (Hassan et al., 2016; Veettil et al., 2017b; Arunah et al., 2020). The National Cancer Registry in Malaysia reported that CRC is the most common cancer in males (16.3 %) while in females it is the second most common type of cancer (10.7 %) (Chandran et al., 2020).

Approximately 80 % of these cases in Malaysia are diagnosed in patients older than 50 years of age, with the majority of them presenting as an advanced disease with a poorer prognosis (Saad et al., 2013; Hassan et al., 2016; Schliemann et al., 2020). Most CRC cases in Malaysia are diagnosed in late stages, therefore leads to high mortality rates (Chandran et al., 2020; Schliemann et al., 2020).

In CRC, the treatment and prognosis decisions are based principally on the TNM staging system (Lugli et al., 2017). Unfortunately, a significant number of CRC cases behave poorly even though being classified as low risk based on their TNM stage (Rogers et al., 2016; Konishi et al., 2018; Deb et al., 2019; Demi et al., 2019b). The TNM staging system also seems to be lacking in forecasting the outcomes of patients within the same stage (Yang et al., 2016; Rogers et al., 2016; Seneviratne, 2018; Deb et al., 2019; Sadek et al., 2020). Thus, the exploration for other prognostic factors of CRC has been a main research attention (Das et al., 2017; Lugli et al., 2017; Poornakala et al., 2019; Ueno et al., 2019; Demir et al., 2019a).

One of the emerging prognostic factors in CRC is Epidermal Growth Factor 2 (HER2) overexpression or amplification by the tumour tissues (Gordian et al., 2019; Wang et al., 2019; Xie et al., 2020; Cuyper et al., 2020). The *HER2* oncogene encodes for a transmembrane glycoprotein receptor that functions as an intracellular tyrosine kinase and is a member of the epidermal growth factor receptor (EGFR) family (Greally et al., 2018a; Wang et al., 2019). The percentage of HER2 overexpression or amplification in CRC varies widely, ranging from 0% - 84% (Blok et al., 2013; Shabbir et al., 2016; Liu et al., 2019).

CRC cases with HER2 positive has been suggested to show a negative prognostic impact of HER2 expression as compared to those with HER2 negative (Siena et al., 2018; Wang et al., 2019; Cuyper et al., 2020). HER2 amplification is also instituted to be a

negative prognosticator toward cetuximab (an anti-EGFR treatment) response, which is a targeted therapy of patients with CRC. Studies also have revealed that activation of HER2 signaling confers resistance to cetuximab (Takegawa et al., 2017; Siena et al., 2018; Xie et al., 2020). For identifying HER2 protein expression and gene amplification on formalin-fixed paraffin-embedded tumour samples (FFPE), immunohistochemistry (IHC) and fluorescent or silver in situ hybridization (FISH or SISH) are the present methods practices respectively (Siena et al., 2018).

Additionally, other factors which have been shown recently to carry prognostic values in CRC include histological parameters designated as “Tumour Budding” (TB) and “Poorly Differentiated Cluster” (PDC) (Demir et al., 2019; Lee et al., 2018; Nearchou et al., 2019). These two parameters are yet not widely adopted by pathologists in their reporting (Nearchou et al 2019). Data on this potential benefit are limited in the literature, as few studies assess both tumour budding and PDC in the same cohort of CRC cases (Barresi, Reggiani Bonetti et al. 2016). TB is defined as presence of de-differentiated single cells or small clusters of up to 4 cells at the invasive front of the cancer, while PDCs are the presence of cancer clusters in the stroma composed of ≥ 5 cancer cells. For tumour budding assessment, International Tumour Budding Consensus Conference (ITBCC) has paved the way for standardization of TB reporting and strongly recommends including the parameter as adjunct to TNM reporting system (Lugli et al., 2017; Ozer et al., 2019; Ueno et al., 2019).

1.2 JUSTIFICATION OF THE STUDY

The incidence of colorectal cancer (CRC) is fast rising in many Asian countries (Veettil et al., 2017b; Kulkarni et al., 2018; Wong et al., 2019; Siegel et al., 2020). This trend is also

expected to be documented in Malaysia in view of an increased prevalence of risk factors such as high fat content diet and diet rich in red meat, obesity, and smoking as well as sedentary lifestyle and a drift towards an aging population (Naing et al., 2017; Veettil et al., 2017b; Arunah Chandran et al., 2020). According to GLOBOCAN 2018, cancer incidence in Malaysia is expected to be double by 2040 (from 43,837 to 84,158 cases) (Schlieman et al., 2020). This condition is associated with high morbidity and mortality hence incurring significant health and financial burden (Ali et al., 2018; Schliemann et al., 2020; Lim et al., 2020).

Multimodality therapy has given rise to improve in the survival of CRC patients although prognoses of some patients are still poor (Pang et al., 2020; Arunah Chandran et al., 2020). Newer targeted therapies are being evaluated and as such it is necessary to evaluate and establish new prognostic and predictive factors other than the conventional ones in order to risk-stratified patients for management purposes (Sayadnejad et al., 2017; Liu et al., 2019; Xie et al., 2020). In this respect HER2 overexpression or amplification has the potential of being a prognostic factor which may impact choice of therapy in CRC (Greally et al., 2018a; Siena et al., 2018; Cuyper et al., 2020). In addition, tumour budding (TB) and poorly differentiated cluster (PDC) parameters may be a promising histologic prognostic factors for assessing the aggressiveness of CRC cases (Lee et al., 2018; Wyk et al., 2019; Ammendola et al., 2020; Chandran et al., 2020).

To the best of our knowledge, there is no published data on the status of HER2 overexpression or amplification, TB and PDC among CRC cases in Kuantan, Pahang, Malaysia. Therefore, there is a strong need for this study to be carried out and it will provide surgeons /oncologists information on the HER2 status in order to subclassify patients

prognostically. It also predicts response to anti- EGFR therapy in CRC cases. Lastly, it will help to identify patients for novel Anti-HER2 targeted treatment.

In this study, we aimed to investigate *HER2* expression status and TB and PDC grades in patients diagnosed with CRC and their associations with tumour grading, staging, lymph node metastasis and lympho-vascular invasion.

1.3 RESEARCH QUESTIONS

1. What is the HER2 expression status in colorectal cancer cases in Kuantan Pahang?
2. What is the status of tumour budding and poorly differentiated cluster in colorectal cancer cases in Kuantan Pahang?
3. What is the association between HER2 status, tumour budding and poorly differentiated cluster in colorectal cancer cases in Kuantan Pahang?
4. What is the association between HER2 status and tumour grade, stage, lymph node metastasis and lymphovascular invasion?
5. What is the association between tumour budding and tumour grade, stage, lymph node metastasis and lymphovascular invasion?
6. What is the association between poorly differentiated cluster and tumour grade, stage, lymph node metastasis and lymphovascular invasion?

1.4 HYPOTHESIS

1. A proportion of colorectal cancer cases have overexpression or amplification of HER2.
2. Higher grade of tumour budding and poorly differentiated cluster in advanced colorectal cancer cases.
3. There is association between HER2 expression status with tumour budding and poorly differentiated cluster in colorectal cancer.
4. There is association between HER2 expression and colorectal cancer grades, stages, lymph node metastasis and lymphovascular invasion.
5. There is association between tumour budding and colorectal cancer stages, grades, lymph node metastasis and lymphovascular invasion.
6. There is association between poorly differentiated cluster and colorectal cancer stages, grades, lymph node metastasis and lymphovascular invasion.